Skip to main content
x
About searching

Search results

  1. ASCO-GI – Jacobio’s KRAS looks competitive in pancreatic

    … cancer with its multi-RAS inhibitor RMC-6236 at ESMO 2023; however, this study excluded G12C mutants. …

    - 01/18/2024 - 14:56

  2. ASCO-GU preview: showdown for Exelixis

    … in neuroendocrine prostate cancer 121 Had data at ESMO 2023; company sold to Merck & Co Keynote-564 …

    - 01/25/2024 - 10:22

  3. Cell cycle niche seeks clinical validation

    … +/- platinum chemo, started Aug 2023; preclinical data at ESMO 2023 AZD8421 AstraZeneca Cycad-1 trial …

    - 01/12/2024 - 17:23

  4. J&J deal cements Ambrx’s transformation

    … cohorts 4-8 the confirmed ORR was 22%.   Source: ESMO 2023.   Any lingering doubts now become …

    - 01/10/2024 - 14:31

  5. Merck’s latest move is in bispecifics

    … toxicity.  In a phase 1/2 study presented at ESMO 2023 HPN328 produced a confirmed response rate of 32% … house Ph1 +/- Keytruda in solid tumours ; data at ESMO 2023 Not yet given Source: Mizuho note, …

    - 06/19/2024 - 16:48

  6. ASCO-GI preview: notable late-breakers

    … 604 KRAS G12C inhibitor with solid tumour data at ESMO 2023 Defiance Leap Therapeutics DKN-01 + …

    - 01/09/2024 - 11:43

  7. Merck KGaA takes a punt on Inspirna’s novel approach

    … with ompenaclid in second-line CRC Source: ESMO 2023.   By way of benchmarks, Folfiri chemo …

    - 01/05/2024 - 13:36

  8. Bristol makes its radiopharma move

    … data are expected late 2025 or early 2026 . At ESMO 2023, phase 1b data from that study found a 29% overall …

    - 01/03/2024 - 17:27

  9. More warnings signs for ATR inhibition

    … ph1/2 +/- gemcitabine/irinotecan in solid tumours at ESMO 2023 IMP9064 Impact Therapeutics First data from ph1/2 +/- senaparib in solid tumours at ESMO 2023 Camonsertib Roche (licensed from Repare) …

    - 11/14/2023 - 10:58

  10. ESMO 2023 movers – who won and who lost?

    ESMO 2023 movers – who won and who lost? …

    - 12/14/2023 - 11:53